X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

LPTX

Closed

Leap Therapeutics Inc

0.2963
-0.0006 (-0.20%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.2969
Day's Range: 0.271 - 0.3195
Send
When Written:
 
0.31
Leap Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing targeted therapies for cancer. The company's pipeline includes several investigational drugs that target specific cancer-related proteins and pathways.

Leap's lead drug candidate is DKN-01, which is being developed for the treatment of gastric and gastroesophageal junction cancer. The company is also developing TRX518, a monoclonal antibody that targets the glucocorticoid-induced TNFR-related protein (GITR) pathway, for the treatment of solid tumors.

In addition to its internal drug development efforts, Leap has collaborations with other companies and academic institutions to advance its research and development programs.

Leap Therapeutics Inc was founded in 2011 and is headquartered in Cambridge, Massachusetts. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "LPTX."

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X